Journey Medical (DERM) has announced that the FDA has granted approval for Emrosi, a treatment targeting inflammatory lesions caused by rosacea in adults. This approval is the result of a collaborative effort with Dr. Reddy's Laboratories Ltd. and is underpinned by promising outcomes from two Phase 3 clinical trials conducted by Journey Medical.
The company stated that it is in the final stages of manufacturing Emrosi for the U.S. market, anticipating that the initial supply will be ready either late in the first quarter or early in the second quarter of 2025. Journey Medical intends to launch Emrosi in the U.S. through its specialized dermatology-focused commercial team.
